For women with genetic risk, twice-a-year MRI beats mammograms

September 13, 2018, University of Chicago Medical Center
DCE-MRI every six months performed well for early detection of invasive breast cancer in genomically stratified high-risk women. Credit: Fred Pineda, postdoctoral fellow, the University of Chicago Medicine

Getting magnetic resonance imaging (MRI) scans twice a year instead of one annual mammogram is far more effective at detecting early breast cancers in young women with a high-risk genetic profile than mammograms alone, according to a research team based at the University of Chicago Medicine and the University of Washington, Seattle.

The results, first presented Dec. 8, 2017 at the annual San Antonio Breast Cancer Symposium and now available online in Clinical Cancer Research, suggest that for women with high-risk genetic , intensive efforts to find small early cancers can be crucial to improving outcomes.

"This study demonstrates for the first time that aggressive breast cancers can be caught early, without excessive recalls or biopsies," said Olufunmilayo Olopade, MD, the Walter L. Palmer Distinguished Service Professor and Associate Dean for Global Health at the University of Chicago Medical Center.

Because of intensive surveillance and high-quality care, the majority of high-risk women in this study did not develop , despite the fact that most of these women had genetic mutations such as BRCA1.

For their study, "Intensive surveillance with bi-annual dynamic contrast-enhanced magnetic resonance imaging downstages breast in BRCA1 mutation carriers," the researchers enrolled 295 women into a clinical trial. The mean age at entry was 43.3 years.

To join the trial, volunteers had to have a lifetime risk for breast-cancer greater than 20 percent. More than half (53%) of the women who enrolled had one of 11 known breast-cancer related genetic abnormalities. Seventy-five of those 157 women had BRCA1 mutations, and 61 had BRCA2 mutations.

The study also included women who had been diagnosed with breast cancer or ductal carcinoma in situ before age 35, or had a mother or sister diagnosed with breast cancer before age 50 (before 40 for those of African ancestry). All study subjects had a panel of genetic tests looking for genes associated with a predisposition to breast cancer.

After evaluation by a physician and a genetic counselor, participants were scheduled to undergo a clinical breast examination and a dynamic contrast-enhanced scan (DCE-MRI) every six months, plus a digital mammogram every 12 months. Those with high-risk mutations who completed five years of the study protocol were offered continued screening.

Over the course of the study, the researchers performed 2,111 DCE-MRIs (on average, about seven for each participant) and 1,223 mammograms (four per participant). They found 17 cancers: four ductal carcinoma in situ and 13 early stage breast cancers.

Fifteen of those cancers occurred in participants with pathogenic mutations. Eleven involved BRCA1, three involved BRCA2, and one involved CDH1. None of the cancers had spread to the lymph nodes. The mean tumor size was 0.61 centimeter (about 1/4 of an inch). All cancers detected during the study were smaller than a centimeter.

Their primary reasons for leaving the study were the cost of health insurance, prophylactic mastectomy, and moved away or changed healthcare provider. Credit: The study authors

The 17 patients who developed a cancer were followed continuously for a median of 5.3 years (range 0.5 to 11 years). All are alive and free of systemic disease. Patient anxiety levels decreased over time and patient-reported quality of life improved. The study authors recommend "further interventional studies evaluating this novel screening approach to personalize assessment and prevention."

In this study, DCE-MRI every 6 months "performed well for early detection of in genomically stratified high-risk women," said Gregory Karczmar, Ph.D., professor of radiology at the University of Chicago. "This is the ultimate goal of breast cancer screening," he added, "detecting node-negative, invasive tumors less than 1 centimeter."

"For these patients, annual mammography did not provide any additional benefit to bi-annual dynamic contrast-enhanced MRI scans," the authors agreed.

Mammograms are routinely used to screen for breast cancer, but they are "not the best option for about 40 percent of women," Karczmar said. "This includes those with dense breasts as well as those with significant genetic risks."

"MRI is much more sensitive than mammography," he added. "It can find invasive breast cancers sooner than mammograms and it can rule out abnormalities that appear suspicious on a mammogram. Unfortunately, MRI is much too expensive for routine screening."

Mammograms will remain important for most women, but for women at high risk who are getting a DCE-MRI every six months, "annual mammograms can be eliminated," Olopade said.

"The central goal of our study was to understand the needs of the highest-risk women," said study co-author Mary Claire King, Ph.D., professor of genome sciences and of medicine at the University of Washington and the American Cancer Society Research Professor for Breast Cancer.

King has advocated for all women to be offered testing for BRCA1 and BRCA2 at about age 30, regardless of personal or family history of cancer, so that women with mutations can take action to prevent cancer in their futures.

"My hope is that mammography and MRI will be used in ways that make sense given a woman's personal genetics," she said. "Women with mutations in BRCA1 or BRCA2 have very different needs for surveillance for disease than women with no mutations in these genes. This is particularly true for healthy young women with mutations. It's truly critical to offer intensive surveillance to still-healthy women with BRCA1 or BRCA2 mutations."

A number of patients withdrew from the study within five years. Their primary reasons for leaving were the cost of health insurance or other payment issues, 27 percent; prophylactic mastectomy, 16 percent; and moved away or changed healthcare provider, 11 percent.

The American Cancer Society (ACS) currently recommends an annual DCE-MRI as well as an annual mammogram for who are at high risk, typically starting at age 30.

Explore further: For women with genetic risk, bi-annual MRI beats mammograms

More information: Rodrigo Santa Guindalini et al, Intensive surveillance with bi-annual dynamic contrast-enhanced magnetic resonance imaging downstages breast cancer in BRCA1 mutation carriers, Clinical Cancer Research (2018). DOI: 10.1158/1078-0432.CCR-18-0200

Related Stories

For women with genetic risk, bi-annual MRI beats mammograms

December 8, 2017
Intensive surveillance including a dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) exam every six months was far more effective in detecting breast cancer in younger women with a high-risk genetic profile than ...

Genetic predisposition to breast cancer due to non-brca mutations in ashkenazi Jewish women

July 20, 2017
Genetic mutations in BRCA1 and BRCA2 increase the risk of breast and ovarian cancer in Ashkenazi Jewish women. A new article published by JAMA Oncology examines the likelihood of carrying another cancer-predisposing mutation ...

Paper identifies genes associated with risk for aggressive breast cancer

August 7, 2018
A new study published in the Journal of the National Cancer Institute has identified specific genes associated with increased risk for triple-negative breast cancer, providing the basis for better risk management.

Team identifies genes that increase risk for triple-negative breast cancer

August 7, 2018
A research team led by Fergus Couch, Ph.D., a geneticist at Mayo Clinic, has identified specific genes associated with an increased risk for developing triple-negative breast cancer. Their research was published in the Journal ...

Breast cancer prognosis may be worse if diagnosis follows 'negative' mammogram

May 3, 2018
(HealthDay)—About 15 percent of breast cancers are diagnosed in the interval between regularly scheduled mammograms, where the last mammogram showed no signs of a cancer.

Abbreviated breast MRI may be additional screening option for dense breasts

November 28, 2017
Among women with dense breast tissue, for whom traditional mammograms are less effective at detecting cancer, who request additional screening after a negative mammogram, abbreviated breast MRI (AB-MR) may be a valuable cancer ...

Recommended for you

Researchers find adult stem cell characteristics in aggressive cancers from different tissues

September 19, 2018
UCLA researchers have discovered genetic similarities between the adult stem cells responsible for maintaining and repairing epithelial tissues—which line all of the organs and cavities inside the body—and the cells that ...

Colon cancer is caused by bacteria and cell stress

September 19, 2018
Researchers at Technical University Munich have reported findings related to the development of colon cancer. "We originally wanted to study the role of bacteria in the intestines in the development of intestinal inflammation," ...

Eating foods with low nutritional quality ratings linked to cancer risk in large European cohort

September 18, 2018
The consumption of foods with higher scores on the British Food Standards Agency nutrient profiling system (FSAm-NPS), reflecting a lower nutritional quality, is associated with an increased risk of developing cancer, according ...

CRISPR screen reveals new targets in more than half of all squamous cell carcinomas

September 18, 2018
A little p63 goes a long way in embryonic development—and flaws in p63 can result in birth defects like cleft palette, fused fingers or even missing limbs. But once this early work is done, p63 goes silent, sitting quietly ...

Could the zika virus fight the brain cancer that killed john McCain?

September 18, 2018
(HealthDay)—Preliminary research in mice suggests that the Zika virus might be turned from foe into friend—enlisted to curb deadly glioblastoma brain tumors.

Enlarged genotype-phenotype correlation for a three-base pair deletion in neurofibromatosis type 1

September 18, 2018
International collaborative research led by Ludwine Messiaen, Ph.D., shows that while a three-base pair, in-frame deletion called p.Met992del in the NF1 gene has a mild phenotype for people with the genetic disorder neurofibromatosis ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.